Signs and symptoms of gastroesophageal junction cancer and stomach cancer may include:
- Feeling bloated after eating
- Feeling full after eating small amounts of food
- Severe, persistent heartburn
- Severe indigestion that is always present
- Unexplained, persistent nausea
- Stomach pain
- Persistent vomiting
- Unintentional weight loss
When to see a doctor
If you have signs and symptoms that worry you, make an appointment with your doctor. Your doctor will likely investigate more common causes of these signs and symptoms first.
In general, cancer begins when an error (mutation) occurs in a cell's DNA. The mutation causes the cell to grow and divide at a rapid rate and to continue living when a normal cell would die. The accumulating cancerous cells form a tumor that can invade nearby structures. And cancer cells can break off from the tumor to spread throughout the body.
Gastroesophageal junction cancer is associated with having gastrointestinal reflux disease (GERD) and, less strongly, with obesity and smoking. GERD is a condition caused by frequent backflow of stomach acid into the esophagus.
There is a strong correlation between a diet high in smoked and salted foods and stomach cancer located in the main part of the stomach. As the use of refrigeration for preserving foods has increased around the world, the rates of stomach cancer have declined.
The main risk factors for gastroesophageal junction cancer are a history of GERD and obesity.
Factors that increase your risk of stomach cancer located in the stomach body include:
- A diet high in salty and smoked foods
- A diet low in fruits and vegetables
- Eating foods contaminated with a fungus called aflatoxin
- Family history of stomach cancer
- Infection with Helicobacter pylori
- Long-term stomach inflammation
- Pernicious anemia
- Stomach polyps
Aug. 29, 2017
- AskMayoExpert. Esophageal and gastric cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Niederhuber JE, et al., eds. Cancer of the stomach and gastroesophageal junction. In: Abeloff 's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. https://www.clinicalkey.com. Accessed March 23, 2016.
- Feldman M, et al. Adenocarcinoma of the stomach and other gastric tumors. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. https://www.clinicalkey.com. Accessed March 23, 2016.
- Gastric cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 23, 2016.
- Gastrointestinal stromal tumors treatment — Patient version (PDQ). National Cancer Institute. http://www.cancer.gov/types/soft-tissue-sarcoma/patient/gist-treatment-pdq. Accessed March 24, 2016.
- Palliative care. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed March 23, 2016.
- Singh S, et al. Physical activity is associated with reduced risk of gastric cancer: A systematic review and meta-analysis. Cancer Prevention Research. 2014;7:12.
- Carr JS, et al. Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. Journal of Gastrointestinal Cancer. 2013;44:143.
- Atasoy A, et al. Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas. https://www.uptodate.com/home. Accessed April 26, 2017.
- Goode EF, et al. Immunotherapy for gastroesophageal cancer. Journal of Clinical Medicine. 2016;5:84.
- Crane SJ, et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. American Journal of Gastroenterology. 2007;102:1596.
- Ajanai JA, et al. Esophageal and esophagogastric junction cancers, version 1.2015. Journal of the National Comprehensive Cancer Network. 2015;13:194.
- Maron SB, et al. Novel targeted therapies for esophagogastric cancer. Surgical Oncology Clinics of North America. 2017;26:293.